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Abstract
Objective: Narcolepsy is a severe sleep disorder that is characterized by excessive daytime sleepiness, cataplexies and a
tendency towards obesity. Recent discoveries indicate that the major pathophysiology is a loss of hypocretin (orexin)
producing neurons due to immunologically mediated degeneration. Visfatin is a recently described proinflammatory
adipokine. It is identical to the immune modulating pre-B-cell colony enhancing factor (PBEF). Our study examines the
hypothesis that visfatin levels are altered in narcoleptic patients.
Methods: For the analysis, a total of n=54 patients (n=18 males and n=36 females) with the diagnosis of narcolepsy
according to DSM-IV and the International Classification of Sleep Disorders were examined (BMI mean 30.365.5, age mean
52.5616.1 years). As a control group 39 unrelated (n=12 males and n=27 females) healthy volunteers with no sleep
disorder according to DSM-IV were included (BMI mean 28.564.6, age mean 51.1613.6 years). Peripheral visfatin levels were
measured using a commercial enzyme immunoassay kit with a measurement range from 0.1–1000 ng/ml. Narcolepsy
symptoms, severity and frequency of symptoms as well as the total duration of various aspects of the symptomatology were
assessed by unstructured and structured clinical interviews in including the Stanford Center for Narcolepsy Sleep Inventory.
Results: Circulating visfatin was found to be significantly increased in HLA DR2 positive narcoleptic patients compared to
controls.
Conclusion: Taken together, our results add to the evidence of disturbed immunological regulation in patients with
narcolepsy.
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Introduction
Narcolepsy is a sleep disorder that affects approximately 0.05%
of the population in Western countries [1]. Typical symptoms
include day time somnolence, cataplexies (emotionally triggered,
sudden, involuntary loss of muscle tone), sleep related hallucina-
tions, sleep paralysis, and automatic behavior [1]. In addition,
narcoleptic patients are more obese than healthy controls [2,3].
On a physiological level, the disorder has been conceptualized as a
disturbance in the regulation of sleep, REM sleep and wake cycles
[1]. Recently, abnormalities in the orexin neurotransmitter system
have been shown to cause narcolepsy-like symptoms in orexin-
knockout mice [4] as well as in narcoleptic canine breeds [5].
Furthermore, a deficiency in orexin levels was found in the liquor
cerebro spinalis and to a much lesser extent in the peripheral
blood of narcoleptic humans [6,7,8]. Orexinergic neurons
originate from the lateral hypothalamus and reach out to most
parts of the central nervous system including the brain stem.
Orexin plays a crucial role in regulating and maintaining sleep/
wakefulness states and energy homeostasis. In most cases,
however, narcolepsy is not associated with abnormalities of
orexinergic genes, and the cause(s) of narcolepsy are still not fully
understood. However, narcolepsy is strongly associated with the
major histocompatibility class II haplotype HLA DRB1*1501-
QB1*0602 [9,10]. Clinical trials using intravenous immunoglob-
ulin infusions in recent onset narcolepsy with cataplexy have led to
improvement in cataplexy in some patients [11]. Despite the fact
that specific antibody markers for narcolepsy are still elusive, an
autoimmune-mediated mechanism is considered the most proba-
ble etiology for narcolepsy and the elucidation of immune markers
is one of the top priorities in narcolepsy research [12,13]. A
number of studies have focused on cytokines. Vgontzas et al.,
1997, reported elevated TNF-a plasma in narcoleptics based on
the analysis of 11 narcoleptics and 10 controls [14]. Hinze-Selch,
in an attempt of replication in nine narcoleptics and controls
reported in 1998 that mitogen-stimulated monocytes of narcolep-
tics secreted more IL-6 than control monocytes, whereas no TNF
abnormalities were found [15]. Okun et al., 2004, measured
plasma levels of TNF-a and IL-6 in 39 narcoleptic patients and in
40 controls and confirmed significantly higher TNF-a and IL-6
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TNF-a and its soluble receptor in 30 narcoleptics and 120 controls
and found elevated levels of the TNF-receptor but not of TNF
itself [17]. Indirect support for an involvement of cytokines in the
pathophysiology of narcolepsy comes from a number of molecular
genetic studies, including one of our own group in which variants
of TNF were associated with narcolepsy [18,19,20].
Fukuhara et al. (2005) identified a molecule that is expressed at
much higher levels in visceral fat than in subcutaneous fat [21].
This molecule, denoted visfatin to indicate its abundance in
visceral fat, turned out to have been already identified as a growth
factor for early B cells called pre-B cell colony-enhancing factor
(PBEF), a 52-kilodalton cytokine also expressed in lymphocytes.
Visfatin exerts insulin-mimetic effects in cultured cells and lowers
plasma glucose levels in mice [21]. Visfatin dose-dependently
upregulates the production of the pro- and anti-inflammatory
cytokines IL-1, IL-1Ra, IL-6, IL-10, and TNF in human
monocytes [22]. These cytokines play a substantial role in a wide
range of infectious and inflammatory diseases including narcolepsy
[16,17,23]. Visfatin has been linked to several inflammatory
disease states such as acute lung injury and rheumatoide arthritis
[24]. In addition, Visfatin is considered to be a putative biomarker
for metabolic syndrome. However, therapeutic intervention with
drugs known to alter insulin resistance and dyslipidemia did not
result in any change in circulating visfatin levels in non-diabetic
patients with elevated risk for macrovascular disease [25]. The role
of visfatin in the pathophysiology of the metabolic syndrome is still
under investigation.
To test the hypothesis that visfatin levels are altered in
narcoleptics we compared peripheral visfatin levels of 54
narcoleptic patients with those of 39 controls.
Methods
Patients
This study is part of a broader effort to clinically and genetically
characterize narcolepsy patients. For the present analysis, a total of
n=54 patients (n=18 males and n=36 females) with the
diagnosis of narcolepsy according to DSM-IV and the Interna-
tional Classification of Sleep Disorders [26] were examined.
Patients were all unrelated and were either from the Department
of Psychiatry, Mainz, or recruited with the help of the Deutsche
Narkolepsie-Gesellschaft, a nationwide German patient organiza-
tion. Most narcoleptic patients visited our department to
participate in the research program. Others who were unable or
unwilling to come but eager to participate were visited by a
member of the research team at home. Total duration of
narcolepsy symptoms, severity of daytime sleepiness and frequency
(0=more than a year ago, 1=within the past year, 2=within the
past month, 3=within the past week, 4=within the past 24 hours)
of the symptoms cataplexies, automatic behaviour, hallucinations
and sleep paralysis were assessed by unstructured and structured
clinical interviews in including the Stanford Center for Narcolepsy
Sleep Inventory (http://med.stanford.edu/school/Psychiatry/
narcolepsy/sleepinventory.pdf). Patients were only enrolled into
the study when unambiguous cataplexies in addition to severe
daytime sleepiness were reported and when sleep laboratory
confirmation of the diagnosis was present in the medical records.
To exclude symptomatic narcolepsies, the medical history was
assessed and a neurologic examination was performed. As a
control group 39 unrelated (n=12 males and n=27 females)
healthy volunteers with no sleep disorder according to DSM-IV
were included. In order to maximise similarities in lifestyle and
habits between patients and controls controls were either spouses
or genetically unrelated aquaintances of the patients. Absence of
narcolepsy or other major sleep disorders was checked by clinical
interview and by the administration of the Stanford Center for
Narcolepsy Sleep Inventory. Blood samples were collected in
patients and controls after a 12-hour fasting period in the morning
between 8:00 and 10:00 am. Samples were immediately
centrifuged, cooled with dry ice and stored at 280uC until the
visfatin measurements. An additional anticoagulated blood smple
was taken for DNA preparation (HLA-testing).
All participants were of Caucasian origin. All participants gave
written, informed consent. No participation fees were paid. The
study design was approved by the local Ethics Committee of the
Federal Chamber of Physicians of Rhineland-Palatinate. For a
general characterisation of patients and controls, please see table 1.
Measurements
Visfatin levels were measured using an enzyme immunoassay kit
from Phoenix Pharmaceuticals (Phoenix Europe GmbH, Karls-
ruhe, Germany) with a measurement range from 0.1–1000 ng/ml.
This enzyme immunoassay kit is designed to detect a specific
peptide and its related peptides based on the principle of
‘‘competitive’’ enzyme immunoassay.
The detection range was 0.1–1000 ng/ml with an inter-assay
variation of less than 14% and intra-assay variation less than 5%
according to the manufacturer.
The unknown concentration in samples can be determined by
extrapolation to the standard curve.
All Patients and controls were HLA typed by standard PCR-
SSO using a commercial kit (Dynal RELI SSO HLA-DRB1 Test;
Invitrogen GmbH, Karlsruhe, Germany).
Table 1. Characterisation of patients and controls.
Characteristics Narcoleptics Controls p-values
n5 4 3 9
Males 18 (33.3%) 12 (30.8%) n.s.
Females 36 (66.6%) 27 (69.2%) n.s.
Age (years) 52.5616.1 51.1613.6 n.s.
(males) 60.4614.7 50.3613.7 n.s.
(females) 48.5615.5 51.5613.7 n.s.
BMI (kg/m
2) 30.365.5 28.564.6 n.s.
(males) 31.164.9 29.564.0 n.s.
(females) 29.865.8 28.064.9 n.s.
Duration of narcolepsy
(years)
32.8617.9 n.a
Age of onset (years) 20.1611.9 n.a.
Symptoms
Daytime somnolence 54 (100%) n.a.
Cataplexies 54 (100%) n.a.
Hallucinations 45 (83%) n.a.
Sleep paralysis 34 (63%) n.a.
Automatic behavior 41 (76%) n.a.
HLA DR2 pos. 46 (85%) 9 (23%)
(males) 16 (89%) 3 (25%)
(females) 30 (83%) 6 (22%)
n.s.=not significant; n.a.=not applicable or not measured
doi:10.1371/journal.pone.0002980.t001
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Descriptive results of continous variables are expressed as
means6SD for Gaussian variables and as median and inter-
quartile range for non-Gaussian variables. Group differences were
tested with the Mann-Whitney-U-Test and the Kruskal-Wallis-
Test. For the assessment of correlations, Spearman correlation
coefficients were calculated. All analyses were two-tailed and
conducted with SPSS software (version 12.0 for Windows). P-
values of p,0.05 were considered to be statistically significant.
Results
Mean visfatin concentrations were elevated in narcoleptic
patients in comparison to age and BMI matched controls. The
median was 33.7 ng/ml in narcoleptics (interquartile range 19.7–
54.4) vs. 19.4 ng/ml in the controls (interquartile range 15.3–31.5;
p=0.036).
Visfatin values did not differ between women and men. The
median for all women (narcoleptic patients and controls) was
26.1 ng/ml (interquartile range 15.3–50.4) and for all men was
25.5 ng/ml (interquartile range 17.3–58.3; p=0.642). The visfatin
values for the female narcoleptics were 38.3 ng/ml (interquartile
range 20.7–54.8) and 27.9 ng/ml for the narcoleptic males
(interquartile range 17.3–58.4; p=0.582) and for the control
women 19.4 ng/ml (women, interquartile range 14.7–28.4) and
21.2 ng/ml for the male controls (interquartile range 17.4–68.6;
p=0.327).
Closer examination of the data revealed that the group
difference between narcoleptics and controls was mainly driven
by the HLA DR2 positive narcoleptics (BMI 31.165.1; p=0.51
compared to controls; age 54.2616.2; p=0.23 compared to
controls). The median of the HLA DR2 positive narcoleptics was
36.2 ng/ml (interquartile range 21.0–57.5) vs. 20.2 ng/ml in
HLA-neg. narcoleptics (interquartile range 12.6–35.2; p=0.036)
vs. 19.4 ng/ml in the controls (interquartile range 15.3–31.5;
p=0.010; figure 1). No differences between HLA positive and
negative controls were apparent. The median of the HLA DR2
positive controls was 19.4 ng/ml (interquartile range 12.7–40.8)
vs. 20.4 ng/ml in HLA-neg. controls (interquartile range 16.0–
36.1; p=0.756).
After the stratification in HLA DR2 positive and negative
patients, there was again no difference between men and women:
The median for HLA-pos. women was 44.2 ng/ml (interquartile
range 25.1–57.5). The median for HLA-pos. men was 27.9 ng/ml
(interquartile range 17.3–95.9; p=0.321). The median for HLA-
neg. woman was 17.7 ng/ml (interquartile range 8.9–28.9). The
median for HLA-neg. men was 29.5 ng/ml (interquartile range
20.0–39.1; p=0.643).
Visfatin was not correlated with age or BMI, neither in the
HLA DR2 positive narcoleptic patients (age: corr. coeff. 0.062,
p=0.684; BMI: corr. coeff. 0.044, p=0.772), in the HLA DR2
negative naroleptic patients (age: corr. coeff. 0.238, p=0.570;
BMI: corr. coeff. 0.204, p=0.629) nor in the control group (age:
c o r r .c o e f f .0 . 3 1 6 ,p = 0 . 0 5 0 ;B M I :c o r r .c o e f f .20.155, p=
0.346).
Finally, we calculated correlations between visfatin levels and
different measures of the frequency and severity of narcoleptic
symptoms, with the age of onset, the BMI and the duration of
narcolepsy. Unexpectedly, we found a sifgnificant correlation
between the self-reported frequency of cataplexies and visfatin
levels in the HLA-DR2 positive male narcoleptics, but not in the
HLA DR2 positive female narcoleptics. All other correlations,
including those calculated with the HLA DR2 negative patients
(data not shown) were non-significant (see table 2).
Discussion
In our analyses, visfatin levels were significantly higher in HLA
DR2 positive narcoleptic patients than in BMI- and age-matched
controls. This result corroborates previous findings, that different
measures of immunological activity are elevated in narcoleptics. A
link between narcolepsy and altered immune functions has been
hypothesized ever since the tight association between narcolepsy
and the HLA-system had been recognized (for an excellent review
see Mignot et al., 1995 [27] and Black 2005 [12]). The TNF-a
system is of additional specific interest because it directly interacts
with the visfatin system. By incubating fat tissue with TNF, Hector
et al., 2007, demonstrated that TNF is a strong inductor of visfatin
mRNA secretion and thus it appears conceivable that elevated
TNF levels in narcoleptic patients contribute to the elevated
visfatin in the present study [28]. On the other hand, visfatin is
able to stimulate secretion of different cytokines such as interleukin
beta, TNF and Il-6 and thus is considered immunomodulating and
proinflammatory (Moschen et al., 2007) [22].
Human narcolepsy may have multiple etiologies and may
develop at least partially on a genetic background. The high
incidence of human leukocyte antigen (HLA)-DR2 haplotypes
among narcoleptics suggests that an autoimmune process is
involved in the pathophysiology of the disease. A relationship
between narcolepsy and a deficiency of the peptide neurotrans-
mitter orexin (hypocretin) has been established [29]. One
hypothesis is that narcolepsy is an autoimmunologic disease that
leads to the specific degeneration of hypothalamic hypocretin-
containing cells. The observation of increased visfatin levels in
narcoleptics is in good accordance with this thesis, because
Figure 1. Boxplot comparing controls with narcoleptics,
outliers above 100 ng/ml (one individual of the control group,
five narcoleptic patients) are not depicted.
doi:10.1371/journal.pone.0002980.g001
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diseases such as as rheumatoid arthritis [30] and diabetes type I
[31]. Moreover, elevated visfatin has been found in conditions that
involve acute immunological activation such as colorectal cancer
and acute lung injury (ALI) [32,33].
In our study, the elevation of visfatin was only found in HLA
DR2 positive narcoleptics, who constitute the vast majority of all
cases, but not in HLA DR2 negative patients, whose visfatin levels
were not distinguishable from the visfatin levels of the controls.
This observation fits excellently in the theroretical framework
described above because it is mainly the HLA DR2 positive
patients who show diminished orexin levels whereas HLA DR2
negative patients tend to display orexin levels comparable to those
of controls [34]. Accordingly, the autoimmune hypothesis of
narcolepsy might be true only for the HLA DR2 positive or the
central orexin deficient form. Therefore, the visfatin results
support existing evidence [34], including molecular genetic
evidence from our own group [27] that HLA DR2 positive and
negative narcolepsy may represent different pathophysiological
entitites leading to a common clinical appearance. In our study, as
in previous studies [20,35,36,37,38,39,40], there was no correla-
tion between age, BMI or gender and visfatin levels. The finding of
a correlation between visfatin levels and frequencies of cataplexies
in male but not female HLA DR2 positive patients was rather
unexpected. Currently, we can not offer an evidentiary explana-
tion. However, the issue of sexual dimorphisms in narcolepsy has
previously been raised in the context of potentially cataplexy
relevant neurotransmitter metabolisation [41].
In summary, our study adds to the growing evidence of subtle
signs of immunological dysfunction in narcoleptic patients.
Because our study is the first study measuring visfatin in
narcoleptic patients, independent replication is necessary before
considering the findings conclusive.
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